Petri

Petri Bio is a biotechnology company focused on developing next-generation therapeutics derived from gut microbes. The company leverages the vast genetic information within the microbiome to discover and develop novel treatments for challenging diseases such as inflammatory bowel disease (IBD) and fatty liver disease. These diseases often have limited effective treatments, making Petri Bio's work particularly impactful. Founded by Shu Li, a Ph.D. in plant biology, and Joseph Schinaman, a biomedical researcher, Petri Bio is committed to using microbial compounds to create new medicines. Their approach involves mining microbial genomes for peptides with therapeutic potential, which they believe could lead to breakthroughs in treating various conditions that are currently underserved by existing pharmaceutical solutions. Petri Bio has also been involved in the development of treatments related to COVID-19, using their platform to identify compounds that could potentially neutralize the virus. Their work has garnered attention and interest from major pharmaceutical companies, and they continue to expand their pipeline to include other critical areas of healthcare.